A detailed history of Legal & General Group PLC transactions in Liquidia Corp stock. As of the latest transaction made, Legal & General Group PLC holds 78,036 shares of LQDA stock, worth $781,140. This represents 0.0% of its overall portfolio holdings.

Number of Shares
78,036
Previous 68,554 13.83%
Holding current value
$781,140
Previous $1.01 Million 7.42%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.96 - $15.71 $113,404 - $148,962
9,482 Added 13.83%
78,036 $936,000
Q1 2024

May 14, 2024

BUY
$11.35 - $16.73 $721,848 - $1.06 Million
63,599 Added 1283.53%
68,554 $1.01 Million
Q3 2023

Nov 14, 2023

SELL
$6.27 - $8.15 $3,881 - $5,044
-619 Reduced 11.11%
4,955 $31,000
Q2 2023

Aug 14, 2023

BUY
$6.63 - $9.9 $1,054 - $1,574
159 Added 2.94%
5,574 $43,000
Q3 2022

Nov 14, 2022

SELL
$3.73 - $8.39 $12,514 - $28,148
-3,355 Reduced 38.26%
5,415 $29,000
Q2 2022

Aug 22, 2022

BUY
$3.37 - $7.55 $29,554 - $66,213
8,770 New
8,770 $38,000
Q2 2021

Aug 12, 2021

SELL
$2.51 - $3.11 $7,437 - $9,214
-2,963 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$2.42 - $3.6 $672 - $1,000
-278 Reduced 8.58%
2,963 $8,000
Q3 2020

Nov 13, 2020

SELL
$4.34 - $8.28 $477 - $910
-110 Reduced 3.28%
3,241 $16,000
Q2 2020

Aug 14, 2020

BUY
$4.86 - $11.44 $7,202 - $16,954
1,482 Added 79.29%
3,351 $28,000
Q1 2020

May 14, 2020

SELL
$3.31 - $7.15 $3,012 - $6,506
-910 Reduced 32.75%
1,869 $9,000
Q4 2019

Feb 13, 2020

BUY
$3.07 - $5.11 $1,651 - $2,749
538 Added 24.01%
2,779 $12,000
Q2 2019

Aug 14, 2019

BUY
$7.92 - $11.39 $8,125 - $11,686
1,026 Added 84.44%
2,241 $18,000
Q1 2019

May 15, 2019

BUY
$10.82 - $21.79 $5,074 - $10,219
469 Added 62.87%
1,215 $14,000
Q3 2018

Nov 20, 2018

BUY
$10.96 - $28.9 $8,176 - $21,559
746 New
746 $20,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $644M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.